Panel Recommends Japan Continue Ban On Tamiflu For Teenagers
This article was originally published in PharmAsia News
Executive Summary
Japan is keeping in place for now its ban on the use of Roche's Tamiflu (oseltamivir) flu drug for teenagers. A panel convened by the Health, Labor and Welfare Ministry recommended the ban be kept in place after reviewing a survey on the risk of abnormal behavior by teens who took the drug. Researchers are calling for more studies to determine the exact cause of the abnormal behavior, some saying it could have been the flu itself and not the drug to treat it that was responsible. The ban on its use in teens took effect just over two years ago, but it also is one of the major treatments for the H1N1 flu now affecting many Japanese. (Click here for more
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.